Thursday, February 18, 2021 3:25:50 PM
Also today Piper 'encouraged' by Immunic datasets for IMU-838
After Immunic filed "an in-depth 8K" with a detailed analysis of the Phase 2 CALVID-1 and Phase 2 PSC studies of IMU-838, Piper Sandler analyst Yasmeen Rahimi said she is "encouraged by both datasets," adding that the topline data from the Phase 2 proof-of-concept study for IMU-838 in 11 primary sclerosing cholangitis, or PSC, "strong." The analyst, who continues to see multiple sclerosis and ulcerative colitis as Immunic's "key value drivers," also said she views COVID-19 and PSC as "call optionalities." Rahimi keeps an Overweight rating and $71 price target on Immunic shares.
Recent IMUX News
- Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States • PR Newswire (US) • 03/20/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:05:28 PM
- Immunic to Participate in Investor and Scientific Conferences in March • PR Newswire (US) • 03/07/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:52:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:51:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:51:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:50:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:50:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:50:05 AM
- Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 • PR Newswire (US) • 02/29/2024 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 11:38:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 11:35:56 AM
- Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/22/2024 11:30:00 AM
- Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update • PR Newswire (US) • 02/15/2024 11:30:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:05:39 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:47:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:55:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/13/2024 09:36:14 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/05/2024 01:30:32 PM
- Immunic to Participate in Investor and Scientific Conferences in February • PR Newswire (US) • 02/01/2024 11:30:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/24/2024 10:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:07:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:06:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:06:28 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM